When was NeuBase Therapeutics founded?

NeuBase Therapeutics was founded in 2009 and raised its 1st funding round 14 years after it was founded.

Where is NeuBase Therapeutics located?

NeuBase Therapeutics is headquartered in Pittsburgh, United States. It is registered at New York, New York.

Who is the current CEO of NeuBase Therapeutics?

Dietrich Stephan of NeuBase Therapeutics.

How many employees does NeuBase Therapeutics have?

As of Mar 01, 2026, the latest employee count at NeuBase Therapeutics is 10 - 49.

Is NeuBase Therapeutics a funded company?

NeuBase Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Jul 07, 2023.

When was the latest funding round of NeuBase Therapeutics?

NeuBase Therapeutics' latest funding was a $***** Post IPO round on Jul 07, 2023, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.33B in funding in 2026 to date.

Where does NeuBase Therapeutics rank among its competitors?

NeuBase Therapeutics ranks 426th amongst 548 active competitors, of which 200 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of NeuBase Therapeutics?

NeuBase Therapeutics' top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

NeuBase Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of genetic medicines for rare and common diseases. The platform PATrOL targets the mutated proteins causing genetic disorders with the gene silencing treatment to optimize the therapeutic approaches in Huntington disease, Myotonic dystrophy, and more.

Website: neubasetherapeutics.com
Social
Email ID: *****@neubasetherapeutics.com
Registered Address: New York, New York

Key Metrics

Founded Year

2009

Location

Pittsburgh, United States

Stage

Deadpooled

Latest Funding Round

Post IPO, Jul 07, 2023, $*****

Ranked

426^th among 548 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Alnylam & 683 more

View NeuBase Therapeutics' full profile

NeuBase Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neubase Therapeutics, Inc. CIN: 1173281 , United States, Active		-	-	-
Ohr Pharmaceutical, Inc CIN: 46-5622433 , United States, Active	Dec 31, 2008	-	33 (As on Sep 30, 2021)	-
NEUBASE THERAPEUTICS INC CIN: 465622433 , United States, Active	Dec 31, 1999	-	2 (As on Dec 31, 2023)	-

NeuBase Therapeutics has raised funding over 1 round.

Here is the list of recent funding rounds of NeuBase Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2023	9305379	Post IPO	5616044	3309941	2231392	7290505

Access funding benchmarks and valuations. Sign up today!

View details of NeuBase Therapeutics's funding rounds and investors

The founders of NeuBase Therapeutics is Dietrich Stephan.

Here are the details of NeuBase Therapeutics' key team members:

Dietrich Stephan: Founder & CEO of NeuBase Therapeutics.
Contact Info: 1 email address

View details of NeuBase Therapeutics's Founder profiles and Board Members

NeuBase Therapeutics' employee count trend

NeuBase Therapeutics has 10 - 49 employees as of Mar 26. Here is NeuBase Therapeutics's employee count trend over the years:

Employee count trend for NeuBase Therapeutics

Uncover NeuBase Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuBase Therapeutics include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of NeuBase Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
9th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
426th	NeuBase Therapeutics 2009, Pittsburgh (United States), Deadpooled	Developer of genetic medicines for rare and common diseases	-	-	25/100